Janjigian YY - Search Results

1

Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.

Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Nakamura Y, et al. Among authors: janjigian yy. Nat Rev Clin Oncol. 2021 Aug;18(8):473-487. doi: 10.1038/s41571-021-00492-2. Epub 2021 Mar 31. Nat Rev Clin Oncol. 2021. PMID: 33790428 Review.

2

Molecularly targeted therapies in advanced gastric cancer.

Janjigian YY, Shah MA. Janjigian YY, et al. Minerva Gastroenterol Dietol. 2011 Mar;57(1):75-88. Minerva Gastroenterol Dietol. 2011. PMID: 21372772 Review.

3

Molecular classification of gastric cancer: a new paradigm.

Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP. Shah MA, et al. Among authors: janjigian yy. Clin Cancer Res. 2011 May 1;17(9):2693-701. doi: 10.1158/1078-0432.CCR-10-2203. Epub 2011 Mar 23. Clin Cancer Res. 2011. PMID: 21430069 Free PMC article.

4

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Janjigian YY, et al. Ann Oncol. 2012 Oct;23(10):2656-2662. doi: 10.1093/annonc/mds104. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689179 Free article.

5

Genomic dysregulation in gastric tumors.

Janjigian YY, Kelsen DP. Janjigian YY, et al. J Surg Oncol. 2013 Mar;107(3):237-42. doi: 10.1002/jso.23263. Epub 2012 Oct 5. J Surg Oncol. 2013. PMID: 23042588 Review.

6

Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.

Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH. Janjigian YY, et al. Am J Clin Oncol. 2014 Apr;37(2):126-30. doi: 10.1097/COC.0b013e318271b14f. Am J Clin Oncol. 2014. PMID: 23211227 Clinical Trial.

7

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS. Park DJ, et al. Among authors: janjigian yy. Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0. Epub 2013 Dec 27. Ann Surg Oncol. 2014. PMID: 24370903

8

Lapatinib in Gastric Cancer: What Is the LOGiCal Next Step?

Janjigian YY. Janjigian YY. J Clin Oncol. 2016 Feb 10;34(5):401-3. doi: 10.1200/JCO.2015.64.2892. Epub 2015 Dec 23. J Clin Oncol. 2016. PMID: 26700116 No abstract available.

9

Current advances in targeted therapies for metastatic gastric cancer: improving patient care.

Aguiar PN Jr, Muniz TP, Miranda RR, Tadokoro H, Forones NM, Monteiro ID, Castelo-Branco P, Janjigian YY, De Mello RA. Aguiar PN Jr, et al. Among authors: janjigian yy. Future Oncol. 2016 Mar;12(6):839-54. doi: 10.2217/fon.15.348. Epub 2016 Feb 3. Future Oncol. 2016. PMID: 26838766 Review.

10

Clinical impact of tumour biology in the management of gastroesophageal cancer.

Lordick F, Janjigian YY. Lordick F, et al. Among authors: janjigian yy. Nat Rev Clin Oncol. 2016 Jun;13(6):348-60. doi: 10.1038/nrclinonc.2016.15. Epub 2016 Mar 1. Nat Rev Clin Oncol. 2016. PMID: 26925958 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page